



truscreen  
a world without  
cervical cancer

## NZX/ASX Announcement

18 July 2022

### TRUSCREEN DIRECTOR NOMINATIONS CLOSING DATE

TruScreen Group Limited (**NZX/ASX: TRU**) (TruScreen or the Company) advises that the 2022 Annual Meeting (AM) of Shareholders of TruScreen will be held at 11am (NZ time) on Tuesday 6 September 2022. The meeting will be held at Link Market Services Level 30 PWC Tower, 15 Customs Street West Auckland and as an online event.

Details of how shareholders can access and participate in the AM will be released with the Notice of Meeting which will be made available to all shareholders and released to NZX/ASX in the coming weeks.

An item of business at the AM will be the re-election and appointment of directors. The closing date for director nominations is 5pm on Monday 1 August 2022.

Nominations may only be made by a shareholder entitled to attend and vote at the Annual Meeting which will be held on 6 September 2022. The nomination must be accompanied by the consent, in writing, of the person nominated and should contain a brief curriculum vitae of the nominee.

Nominations should be addressed to:

Guy Robertson

TruScreen Chief Financial Officer & Company Secretary

Email: [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com) or [info@truscreen.com](mailto:info@truscreen.com)

This announcement was approved for release by the Board.

-ENDS-

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Juliet Hull

Chief Executive Officer

[juliethull@truscreen.com](mailto:juliethull@truscreen.com)

Guy Robertson

Chief Financial Officer

[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)



## About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for TruScreen is significant.